In Wednesday’s Wall Street session, Nuvation Bio Inc (NYSE:NUVB) shares traded at $2.03, down -6.45% from the previous session.
NUVB stock price is now 0.15% away from the 50-day moving average and -17.14% away from the 200-day moving average. The market capitalization of the company currently stands at $690.73M.
With the price target of $6, Citizens JMP recently initiated with Mkt Outperform rating for Nuvation Bio Inc (NYSE: NUVB). On March 27, 2024, Jefferies Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock increasing its target price from $1.40 to quote $10, while ‘BTIG Research’ rates the stock as ‘Buy’
In other news, Liu Dongfang, CHIEF MEDICAL OFFICER sold 20,000 shares of the company’s stock on May 02 ’25. The stock was sold for $50,024 at an average price of $2.50. Upon completion of the transaction, the CHIEF MEDICAL OFFICER now directly owns 12,000 shares in the company, valued at $24360.0. An SEC document containing details of the transaction can be found on the SEC’s website. On May 02 ’25, Officer DONGFANG LIU bought 20,000 shares of the business’s stock. A total of $45,400 was incurred on buying the stock at an average price of $2.27. A total of 33.36% of the company’s stock is owned by insiders.
During the past 12 months, Nuvation Bio Inc has had a low of $1.54 and a high of $3.97. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 9.01, and a quick ratio of 9.01.
The net profit margin was -5534.21% and return on equity was -119.66% for NUVB.
